Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Tuesday, 23 October 2012
AstraZeneca and Ironwood announce linaclotide collaboration for China AstraZeneca and Ironwood Pharmaceuticals, Inc. announced today an agreement to co-develop and co-commercialise Ironwood’s linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) agonist approved by the US Food and Drug Administration, in August, for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
Monday, 8 October 2012
AstraZeneca and Ardelyx announce worldwide licensing deal for NHE3 Inhibitor Programme for complications of renal disease, including diabetes-induced renal disease AstraZeneca and Ardelyx today announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme
Wednesday, 26 September 2012
AstraZeneca collaborates with Roche Diagnostics to advance personalised healthcare across therapeutic areas AstraZeneca today announced it has entered into a collaboration agreement with Roche Diagnostics
Download our brochure

Download your comprehensive guide to partnering with us.

Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar